232 related articles for article (PubMed ID: 24022806)
1. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update.
Franchini M; Coppola A; Rocino A; Santagostino E; Tagliaferri A; Zanon E; Morfini M;
Semin Thromb Hemost; 2013 Oct; 39(7):752-66. PubMed ID: 24022806
[TBL] [Abstract][Full Text] [Related]
2. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
Franchini M; Tagliaferri A; Mengoli C; Cruciani M
Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
[TBL] [Abstract][Full Text] [Related]
3. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
4. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
Peyvandi F; Miri S; Garagiola I
Front Immunol; 2020; 11():591878. PubMed ID: 33552050
[TBL] [Abstract][Full Text] [Related]
5. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
6. Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors.
Franchini M; Frattini F; Crestani S; Bonfanti C
Hematology; 2013 Jul; 18(4):183-90. PubMed ID: 23394381
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of inhibitors and current treatment strategies.
Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
[TBL] [Abstract][Full Text] [Related]
10. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
11. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.
Kreuz W; Ettingshausen CE; Zyschka A; Oldenburg J; Saguer IM; Ehrenforth S; Klingebiel T
Semin Thromb Hemost; 2002 Jun; 28(3):285-90. PubMed ID: 12098090
[TBL] [Abstract][Full Text] [Related]
13. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.
Santagostino E; Young G; Carcao M; Mannucci PM; Halimeh S; Austin S
Expert Rev Hematol; 2018 Feb; 11(2):87-97. PubMed ID: 29258406
[TBL] [Abstract][Full Text] [Related]
14. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
15. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
16. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
17. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
[TBL] [Abstract][Full Text] [Related]
18. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
Musso R
Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
[TBL] [Abstract][Full Text] [Related]
20. The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
